<p>Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population</p>

Abstract

Participation in the PSP, higher income, and using a specialty pharmacy were associated with lower odds of abandoning ADA therapy, whereas increased copayments were associated with greater abandonment. PSPs should be considered to improve initiation of ADA therapy.